Daewoong

Daewoong Co., Ltd. (003090) sits at the top of the Daewoong Group's governance structure, having converted to a holding company in 2002, and its own revenue comes mainly from brand royalties, rental income, and management fees charged to subsidiaries rather than from operating businesses of its own.

The core subsidiary is Daewoong Pharmaceutical, which runs the group's prescription drug and aesthetics businesses, alongside Daewoong Bio (raw and finished pharmaceutical products), Daewoong Development (real estate), and KOSPI-listed Hanall Biopharma, which develops autoimmune disease therapeutics.

Daewoong Pharmaceutical is pursuing a '1 Product, 1 Trillion Won' strategy built around three innovative drugs -- the botulinum toxin Nabota, the GERD treatment Fexuclue, and the diabetes drug Envlo -- complemented by over-the-counter products such as Ursa, health supplements, and the digital healthcare service ThynC.

Hanall Biopharma, of which Daewoong Pharmaceutical holds roughly a 30.8% controlling stake, has licensed out its FcRn antibody candidate IMVT-1402 to Immunovant, a Roivant Sciences affiliate, and is conducting late-stage trials in indications including Graves' disease.

Nabota is sold under the brand Jeuveau in the United States through partner Evolus and as Nuceiva in Europe, competing domestically with Medytox and Hugel and internationally with global players including AbbVie (Allergan).

Fexuclue continues to expand its share of the domestic P-CAB (potassium-competitive acid blocker) market and obtained regulatory approval in China in September 2025 to prepare for overseas expansion.

Because the holding company's consolidated financial statements incorporate the full results of Daewoong Pharmaceutical and other subsidiaries, the direction of the holding company's earnings is largely driven by the operating performance of Daewoong Pharmaceutical.

Consolidated revenue rose for four straight years, from KRW 1.697 trillion in 2022 to KRW 1.814 trillion in 2023, KRW 1.937 trillion in 2024, and KRW 2.068 trillion in 2025, showing steady top-line growth.

Operating profit, however, fluctuated -- KRW 207.3 billion in 2022, KRW 195.6 billion in 2023, KRW 281.9 billion in 2024, and KRW 261.8 billion in 2025 -- and the operating margin eased from 14.6% in 2024 to 12.7% in 2025.

Owner net income showed even larger swings, plunging from KRW 152.7 billion in 2023 to KRW 57.9 billion in 2024 before rebounding sharply to KRW 175.1 billion in 2025.

This divergence from the operating-profit trend suggests that changes in profit allocation to non-controlling interests at subsidiaries with significant minority stakes, such as Hanall Biopharma, along with equity-method and one-off items, materially affected the owner's share of net income.

Looking at recent quarters, revenue of KRW 542.2 billion and operating profit of KRW 80.5 billion in Q3 2025 gave way to a slight revenue dip to KRW 516.3 billion and a sharp operating profit drop to KRW 34.8 billion in Q4 2025, yet owner net income actually rose to KRW 69.9 billion, hinting at possible one-off factors.

Q1 2026 revenue fell to KRW 492.7 billion, the lowest in the trailing four-quarter window, marking a pause, with operating profit also easing to KRW 47.8 billion.

Q2 2026 revenue rebounded to KRW 570.8 billion, the highest in the window, and operating profit recovered sharply to KRW 76.6 billion, but owner net income slipped slightly to KRW 34.1 billion from KRW 35.3 billion the prior quarter, reaffirming the gap between operating profit and owner net income.

The sum of owner net income over the trailing four quarters (Q3 2025-Q2 2026) reached KRW 179.4 billion, running above the full-year 2025 figure of KRW 175.1 billion.

The global botulinum toxin (Botox-type) market continues to grow on the back of expanding aesthetic and therapeutic indications and rising demand from emerging markets; among Korean players, Daewoong Pharmaceutical (Nabota) competes with Hugel and Medytox domestically, while AbbVie (Allergan) remains the largest global operator.

Nabota has expanded its overseas revenue mix by securing approvals from major regulators including the US FDA, European EMA, and Health Canada, reportedly posting an average annual sales growth rate of 57% from 2019 to 2025.

Domestically, the GERD treatment market is shifting from conventional PPIs (proton pump inhibitors) toward P-CAB class drugs, a trend in which Fexuclue continues to gain share.

On the other hand, the ongoing trade-secret infringement lawsuit with Medytox has fed into a broader controversy over botulinum toxin strain origins across the domestic industry, a factor cited as affecting both industry-wide credibility and company-specific risk.

In digital healthcare, the hospital monitoring service ThynC has been expanding bed-level penetration, drawing attention as a growth pillar outside traditional pharmaceuticals, though the high share of usage-linked contracts means revenue realization lags behind installation growth.

In the autoimmune disease therapeutics market where subsidiary Hanall Biopharma operates, global competition among FcRn inhibitor candidates is active, an industry characteristic in which clinical trial outcomes can materially move enterprise value.

In its recent earnings communications, Daewoong Pharmaceutical indicated that improvement should continue in the second half of 2026 as the inventory adjustment impact on Fexuclue eases and new drug pipeline achievements gain traction.

Nabota has signed export agreements with eight countries across the Middle East and North Africa and, following approval in Saudi Arabia, plans to expand launches into the United Arab Emirates, Qatar, and Kuwait in the first half of 2027.

In Europe, filler products have launched in five countries including the UK and Germany as part of an aesthetics business expansion combining toxin and filler offerings, while construction continues on a new plant with annual capacity of 16 million vials targeted for 2027 startup.

Fexuclue is pursuing additional indications beyond its current four approvals -- including maintenance therapy, non-erosive reflux disease, peptic ulcer, and an injectable formulation -- which could widen its prescribing scope if approved.

Hanall Biopharma is scheduled to disclose IMVT-1402 clinical data for Graves' disease, rheumatoid arthritis, and cutaneous lupus erythematosus in the second half of 2026, results that could shift how the group's overall pipeline value is assessed.

At the same time, given that Medytox's appellate damages claim has been sharply increased to KRW 500 billion, how the litigation proceeds is likely to continue affecting the company's contingent liability and accounting loss-provision estimates.